A Pharmacokinetic Study of MCI-186, a Novel Drug for Cerebrovascular Disease in Elderly and Young Healthy Subjects

Japanese Journal of Clinical Pharmacology and Therapeutics

Volumn 28, Issue 3, 1997, Pages 693-702

  Yokota, Shinichi ^a   Kumagai, Yuji ^a   Uchiumi, Mitsutomo ^a   Isawa, Shinano ^a   Murasaki, Mitsukuni ^a   Akimoto, Kei ^b   Iwamoto, Masato ^b   Yuasa, Takayuki ^b   Iwano, Masao ^b  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

cerebrovascular disease; elderly subjects; MCI 186; pharmacokinetics

Indexed keywords

EID: 0344089490     PISSN: 03881601     EISSN: 18828272     Source Type: Journal    
DOI: 10.3999/jscpt.28.693     Document Type: Article

References (14)

1. Watanabe, T., Yuki, S., Egawa, M., et al.: Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp.Ther., 268: 1597-1604 (1994).
2. Yamamoto, Y., Kuwahara, T., Watanabe, K., et al.: Antioxidant activity of 3-methyl-1-pheny1-2-pyrazolin-5-one. Redox Report, 2: 333-338 (1996).
3. Watanabe, T., Morita, I., Nishi, H., et al.: Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukotriens and Essential Fatty Acids, 33: 81-87 (1988).
4. Watanabe, T. and Egawa, M.: Effects of an antistroke agent MCI-186 on cerebral arachidonate cascade. J. Pharmacol. Exp.Ther., 271: 1624-1629 (1994).
5. Abe, K., Yuki, S. and Kogure, K.: Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke, 19: 480-485 (1988).
6. Nishi, H., Watanabe, T., Sakurai, H., et al.: Effect of MCI-186 on brain edema in rats. Stroke, 20: 1236-1240 (1989).
7. Bottcher, J., Bassmann, H. and Scuppel, R.: Qantification of norantipyrine sulfate and norantipyrine glucuronide as major metabolies of antipyrine in man and rat. J. Pharm. Pharmacol., 36: 391-398 (1984).
8. Greenblatt, D. J., Sellers, E. M. and Shader, R. I.: Drug disposition in old age. N. Engl. J. Med., 306: 1081-1088 (1982).
9. Dawling, S. and Crome, P.: Clinical pharmacokinetics considerations in the elderly. Clin. Pharmacokinet., 17: 236-263 (1989).
10. Divoll, M., Abernethy, D. R., Ameer, B., et al.: Acetaminophen kinetics in the elderly. Clin. Pharmacol. Ther., 31: 151-156 (1982).
11. Kendall, M. J. and Quarterman, C. P.: The effect of age on the pharmacokinetics of oxprenolol. Int. J. Clin. Pharmacol. Ther. Toxicol., 20: 101-104 (1982).
12. Kraus, W., Desmond, P. V., Marshell, J. P., et al.: Effects of aging and liver disease on disposition of lorazepam. Clin. Pharmacol. Ther., 24: 411-419 (1978).
13. Miners, J. O., Penhall, R., Robson, R. A., et al.: Comparison of paraceramol metabolism in young adult and elderly males. Eur. J. Clin. Pharmacol., 35: 157-160 (1988).
14. Greenblatt, D. J., Allen, M. D., Locniskar, A., et al.: Lorazepam kinetics in the elderly. Clin. Pharmacol. Ther., 26: 103-113 (1979).